{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:02:45Z","timestamp":1761238965530,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Science and Technology Research Projects of Chongqing","award":["No. cstc2020jsyj-zzysbAX0024"],"award-info":[{"award-number":["No. cstc2020jsyj-zzysbAX0024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Research and development of pediatric drug faces many difficulties and pediatric clinical trials remain a challenge. Since 2011, a series of measures have been taken to encourage research, development of drugs for pediatric patients in China. In this study, we analyzed pediatric clinical trials conducted in China to provide reference for research and development of pediatric drugs and formulation of relevant policies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a cross-sectional observational study of pediatric trials registered in the Drug Trial Registration and Information Publication Platform before Oct. 31, 2021. All trials that recruited children (under 18\u2009years old as defined in China) were retrieved and general characteristics of the trials and the research drugs were extracted and analyzed. The data were extracted and statistically analyzed by excel 2010 and SPSS 22.0, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 588 registered pediatric clinical trials, which accounted for 3.94% of the total registered trials. The overall average annual growth rate of the number of trials from 2013 to 2020 was 14.47% (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Of the 588 trials included, there were 312 trials (53.06%) with only children as subjects, 127 trials (21.60%) with research drugs only for children use, and the median of target subject number was 320 with the range of 8 to 600,000. The sponsors and the principal investigators were mainly located in the eastern and northern China. 325 trials were vaccine trials, and the dosage form was mainly injection. There were 98 non-vaccine biological product trials (mainly injections), 135 chemical compound drug trials (mainly tablets), 30 traditional Chinese medicine\/natural drugs (mainly granules). Indications of the non-vaccine drugs were mainly diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The number of pediatric clinical trials in China has increased these years. To further promote pediatric clinical trials and motivate pediatric appropriate drug marketing application and administrative approval, conducting large pediatric clinical trials, further development of dosage forms suitable for children with special attention to neonates and prematurity, and improving uneven geographical distribution of sponsors and researchers are the current challenges.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-022-03208-2","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T05:02:33Z","timestamp":1647579753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current situation of pediatric clinical trials in China: focus on trials for drug marketing application and administrative approval"],"prefix":"10.1186","volume":"22","author":[{"given":"Lin","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuntao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujuan","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bennian","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nange","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maolin","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7507-2410","authenticated-orcid":false,"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"3208_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1208\/s12249-021-02076-w","volume":"22","author":"K Wang","year":"2021","unstructured":"Wang K, Jiang K, Wei X, Li Y, Wang T, Song Y. Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development. AAPS PharmSciTech. 2021;22:208.","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"3208_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/jpids\/piaa136","volume":"10","author":"A Beleck","year":"2021","unstructured":"Beleck A, Nachman S. Understanding Pediatric Drug Lag Time: Review of Selected Drug Package Inserts. J Pediat Inf Dis Soc. 2021;10(4):509\u201313.","journal-title":"J Pediat Inf Dis Soc"},{"issue":"2","key":"3208_CR3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s43441-020-00218-z","volume":"55","author":"E Ueyama","year":"2021","unstructured":"Ueyama E, Kaneko M, Narukawa M. Analysis of pediatric drug approval lag in Japan. Ther Innov Regul Sci. 2021;55(2):336\u201345.","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"3208_CR4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.xphs.2020.12.036","volume":"110","author":"I Vieira","year":"2021","unstructured":"Vieira I, Sousa JJ, Vitorino C. Paediatric Medicines \u2013 Regulatory Drivers, Restraints, Opportunities and Challenges. J Pharm Sci. 2021;110(4):1545\u201356.","journal-title":"J Pharm Sci"},{"issue":"6","key":"3208_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40272-017-0261-1","volume":"19","author":"PA Tomasi","year":"2017","unstructured":"Tomasi PA, Egger GF, Pallidis C, Raymond AS. Enabling development of paediatric medicines in Europe: 10 years of the EU paediatric regulation. Pediatr Drugs. 2017;19(6):505\u201313.","journal-title":"Pediatr Drugs"},{"issue":"4","key":"3208_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/archdischild-2019-318676","volume":"106","author":"FB Lagler","year":"2021","unstructured":"Lagler FB, Hirschfeld S, Kindblom JM. Challenges in clinical trials for children and young people. Arch Dis Child. 2021;106(4):321\u20135.","journal-title":"Arch Dis Child"},{"issue":"6","key":"3208_CR7","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1007\/s11096-015-0191-3","volume":"37","author":"P Joret-Descout","year":"2015","unstructured":"Joret-Descout P, Prot-Labarthe S, Brion F, Bataille J, Hartmann JF, Bourdon O. Off-label and unlicensed utilisation of medicines in a French paediatric hospital. Int J Clin Pharm. 2015;37(6):1222\u20137.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"3208_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1186\/1471-2458-13-631","volume":"13","author":"H Knopf","year":"2013","unstructured":"Knopf H, Wolf IK, Sarganas G, Zhuang W, Rascher W, Neubert A. Off-label medicine use in children and adolescents: results of a population-based study in Germany. BMC Public Health. 2013;13(1):631.","journal-title":"BMC Public Health"},{"issue":"2","key":"3208_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/pch\/21.2.83","volume":"21","author":"J Corny","year":"2016","unstructured":"Corny J, Bailey B, Lebel D, Bussi\u00e8res JF. Unlicensed and off-label drug use in paediatrics in a mother-child tertiary care hospital. Paediatr Child Health. 2016;21(2):83\u20137.","journal-title":"Paediatr Child Health"},{"issue":"1","key":"3208_CR10","first-page":"48","volume":"59","author":"J Sla\u017eneva","year":"2012","unstructured":"Sla\u017eneva J, Kov\u00e1cs L, Ku\u017eelov\u00e1 M. Off-label drug use among hospitalized children: identifying extent and nature. Eur Pharm J. 2012;59(1):48\u201354.","journal-title":"Eur Pharm J"},{"issue":"1","key":"3208_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","volume":"176","author":"T Eguale","year":"2016","unstructured":"Eguale T, Buckeridge DL, Verma A, Winslade NE, Benedetti A, Hanley JA, et al. Association of off-label drug use and adverse drug events in an adult population. JAMA Inte Med. 2016;176(1):55\u201363.","journal-title":"JAMA Inte Med"},{"issue":"3","key":"3208_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1574886313666180619120406","volume":"13","author":"AD Pratico","year":"2018","unstructured":"Pratico AD, Longo L, Mansueto S, Gozzo L, Barberi I, Tiralongo V, et al. Off-label use of drugs and adverse drug reactions in pediatric units: a prospective, multicenter study. Curr Drug Saf. 2018;13(3):200\u20137.","journal-title":"Curr Drug Saf"},{"key":"3208_CR13","doi-asserted-by":"publisher","first-page":"104412","DOI":"10.1016\/j.phrs.2019.104412","volume":"148","author":"W Wu","year":"2019","unstructured":"Wu W, Tang Z, Chen J, Gao Y. Pediatric drug development in China: Reforms and challenges. Pharmacol Res. 2019;148:104412.","journal-title":"Pharmacol Res"},{"key":"3208_CR14","unstructured":"State Health and Family Planning Commission. Several Opinions on Safeguarding Drug Use for Children. 2014. Available from: http:\/\/www.nhc.gov.cn\/yaozs\/s3581\/201405\/e51354d631944fa68aac0c4d9585f291.shtml. Accessed 17 Nov 2021."},{"key":"3208_CR15","unstructured":"General office of the national health commission. General office of the ministry of industry and information technology, general department of the state administration of food and drug administration. 2019. Available from: http:\/\/www.gov.cn\/zhengce\/zhengceku\/2019-11\/18\/content_5453049.htm. Accessed 30 Mar 2020."},{"key":"3208_CR16","unstructured":"Drug Trial Registration and Information Publication Platform. Available from: http:\/\/www.chinadrugtrials.org.cn\/index.html. Accessed 1 Nov 2021."},{"key":"3208_CR17","unstructured":"Announcement of the State Food and Drug Administration on the information platform for drug clinical studies (no. 28): National Medical Products Administration. 2013. Available from: https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20130906120001263.html. Accessed 1 Nov 2021."},{"issue":"10","key":"3208_CR18","doi-asserted-by":"publisher","first-page":"e017719","DOI":"10.1136\/bmjopen-2017-017719","volume":"7","author":"CW Jones","year":"2017","unstructured":"Jones CW, Safferman MR, Adams AC, Platts-Mills TF. Discrepancies between ClinicalTrials.gov recruitment status and actual trial status: a cross-sectional analysis. BMJ Open. 2017;7(10):e017719.","journal-title":"BMJ Open"},{"key":"3208_CR19","doi-asserted-by":"publisher","first-page":"e000618","DOI":"10.1136\/bmjpo-2019-000618","volume":"4","author":"GX Hao","year":"2020","unstructured":"Hao GX, Yuan XX, Guo W, Quan XY, Qi XJ, Wang TY, et al. Paediatric drugs trials in China. BMJ Paediatr Open. 2020;4:e000618.","journal-title":"BMJ Paediatr Open"},{"issue":"1","key":"3208_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12887-021-02658-4","volume":"21","author":"Y Zhong","year":"2021","unstructured":"Zhong Y, Zhang X, Zhou L, Li L, Zhang T. Updated analysis of pediatric clinical studies registered in ClinicalTrials. gov, 2008\u20132019. BMC Pediatr. 2021;21(1):212.","journal-title":"BMC Pediatr"},{"key":"3208_CR21","unstructured":"National Bureau of Statistics. Available from: https:\/\/data.stats.gov.cn\/easyquery.htm?cn=C01&zb=A0301&sj=2017. Accessed 1 Nov 2021."},{"issue":"1","key":"3208_CR22","doi-asserted-by":"publisher","first-page":"e20183532","DOI":"10.1542\/peds.2018-3532","volume":"144","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Huang L, Zhou X, Zhang X, Ke Z, Wang Z, et al. Characteristics and workload of pediatricians in China. Pediatrics. 2019;144(1):e20183532.","journal-title":"Pediatrics"},{"issue":"3","key":"3208_CR23","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.clinthera.2016.01.012","volume":"38","author":"K Tsukamoto","year":"2016","unstructured":"Tsukamoto K, Carroll KA, Onishi T, Matsumaru N, Brasseur D, Nakamura H. Improvement of pediatric drug development: regulatory and practical frameworks. Clin Ther. 2016;38(3):574\u201381.","journal-title":"Clin Ther"},{"key":"3208_CR24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.cct.2016.03.002","volume":"47","author":"A England","year":"2016","unstructured":"England A, Wade K, Smith PB, Berezny KY, Laughon MM. Optimizing operational efficiencies in early phase trials: The Pediatric Trials Network experience. Contemp Clin Trials. 2016;47:376\u201382.","journal-title":"Contemp Clin Trials"},{"key":"3208_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jpeds.2020.06.058","volume":"227","author":"JA Lonhart","year":"2020","unstructured":"Lonhart JA, Edwards AR, Agarwal S, Lucas BP, Schroeder AR. Consent rates reported in published pediatric randomized controlled trials. J Pediatr. 2020;227:281\u20137.","journal-title":"J Pediatr"},{"key":"3208_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.conctc.2017.11.005","volume":"9","author":"RG Greenberg","year":"2018","unstructured":"Greenberg RG, Gamel B, Bloom D, Bradley J, Jafri HS, Hinton D, et al. Parents' perceived obstacles to pediatric clinical trial participation: Findings from the clinical trials transformation initiative. Contemp Clin Trials Commun. 2018;9:33\u20139.","journal-title":"Contemp Clin Trials Commun"},{"issue":"1","key":"3208_CR27","doi-asserted-by":"publisher","first-page":"e2032106","DOI":"10.1001\/jamanetworkopen.2020.32106","volume":"4","author":"EM Weiss","year":"2021","unstructured":"Weiss EM, Olszewski AE, Guttmann KF, Magnus BE, Li S, Shah AR, et al. Parental factors associated with the decision to participate in a neonatal clinical trial. JAMA Netw Open. 2021;4(1):e2032106.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"3208_CR28","doi-asserted-by":"publisher","first-page":"e2020049771","DOI":"10.1542\/peds.2020-049771","volume":"148","author":"SM Cho","year":"2021","unstructured":"Cho SM, Serghiou S, Ioannidis JP, Klassen TP, Contopoulos-Ioannidis DG. Large Pediatric Randomized Clinical Trials in ClinicalTrials.gov. Pediatrics. 2021;148(3):e2020049771.","journal-title":"Pediatrics"},{"issue":"4","key":"3208_CR29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/pharmaceutics12040316","volume":"12","author":"JM Delmoral-Sanchez","year":"2020","unstructured":"Delmoral-Sanchez JM, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Andres Navarro-Ruiz A, Bermejo M. Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019. Pharmaceutics. 2020;12(4):316.","journal-title":"Pharmaceutics"},{"key":"3208_CR30","doi-asserted-by":"publisher","first-page":"120296","DOI":"10.1016\/j.ijpharm.2021.120296","volume":"597","author":"KA Mfoafo","year":"2021","unstructured":"Mfoafo KA, Omidian M, Bertol CD, Omidi Y, Omidian H. Neonatal and pediatric oral drug delivery: Hopes and hurdles. Int J Pharm. 2021;597:120296.","journal-title":"Int J Pharm"},{"issue":"5","key":"3208_CR31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1177\/2168479019837522","volume":"53","author":"E Yen","year":"2019","unstructured":"Yen E, Davis JM, Milne CP. Impact of regulatory incentive programs on the future of pediatric drug development. Ther Innov Regul Sci. 2019;53(5):609\u201314.","journal-title":"Ther Innov Regul Sci"},{"key":"3208_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jpeds.2017.08.011","volume":"192","author":"RM Ward","year":"2018","unstructured":"Ward RM, Benjamin DK, Davis JM, Gorman RL, Kauffman R, Kearns GL, et al. The need for pediatric drug development. J Pediatr. 2018;192:13\u201321.","journal-title":"J Pediatr"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03208-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-022-03208-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03208-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T05:03:21Z","timestamp":1647579801000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-022-03208-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3208"],"URL":"https:\/\/doi.org\/10.1186\/s12887-022-03208-2","relation":{},"ISSN":["1471-2431"],"issn-type":[{"type":"electronic","value":"1471-2431"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"27 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No administrative permission was required to access the raw data used in this study, the data used in this study was anonymised before its use, and no specific ethical approval was sought for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest in their authorship or publication of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}